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Simple Summary: A majority of breast cancer deaths are caused by aggressive molecular subtypes
that are at high risk of progression. Patients with high-risk breast cancer commonly receive first-line
systemic chemotherapy. Chemotherapy exerts direct cytotoxic effects on proliferating cancer cells.
In addition, significant effects of chemotherapy are mediated through immune-boosting anti-cancer
mechanisms that counteract immunosuppressive tumor-associated macrophages (TAMs). The aim of
our study was to evaluate the potential prognostic value of the prevalence and the spatial localization
of CD163+ TAMs in tumor tissue from breast cancer patients treated with chemotherapy after surgery.
We developed a novel algorithm that identifies CD163+ TAMs in an objective manner and quantifies
spatial interactions between CD163+ TAMs and cancer cells using distance-based metrics. Our results
demonstrate that close spatial proximity of CD163+ TAMs to cancer cells and the average number
of CD163+ cells either directly adjacent to or within communicating distance of each cancer cell are
independent predictors of unfavorable prognosis in breast cancer.
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Abstract: Tumor-associated macrophages (TAMs) promote progression of breast cancer and other
solid malignancies via immunosuppressive, pro-angiogenic and pro-metastatic effects. Tumorpromoting TAMs tend to express M2-like macrophage markers, including CD163. Histopathological
assessments suggest that the density of CD163-positive TAMs within the tumor microenvironment is
associated with reduced efficacy of chemotherapy and unfavorable prognosis. However, previous
analyses have required research-oriented pathologists to visually enumerate CD163+ TAMs, which is
both laborious and subjective and hampers clinical implementation. Objective, operator-independent
image analysis methods to quantify TAM-associated information are needed. In addition, since
M2-like TAMs exert local effects on cancer cells through direct juxtacrine cell-to-cell interactions,
paracrine signaling, and metabolic factors, we hypothesized that spatial metrics of adjacency of
M2-like TAMs to breast cancer cells will have further information value. Immunofluorescence histocytometry of CD163+ TAMs was performed retrospectively on tumor microarrays of 443 cases of
invasive breast cancer from patients who subsequently received adjuvant chemotherapy. An objective
and automated algorithm was developed to phenotype CD163+ TAMs and calculate their density
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within the tumor stroma and derive several spatial metrics of interaction with cancer cells. Shorter
progression-free survival was associated with a high density of CD163+ TAMs, shorter median
cancer-to-CD163+ nearest neighbor distance, and a high number of either directly adjacent CD163+
TAMs (within juxtacrine proximity <12 µm to cancer cells) or communicating CD163+ TAMs (within
paracrine communication distance <250 µm to cancer cells) after multivariable adjustment for clinical
and pathological risk factors and correction for optimistic bias due to dichotomization.
Keywords: tumor-associated macrophages; cancer biomarkers; tumor immune microenvironment;
spatially-resolved immunohistochemistry data; marked point patterns; nearest neighbor distance;
microscopic image analysis; quantitative pathology; spatial interactions; breast cancer

1. Introduction
Despite improvements in screening, diagnosis, therapies, and surgery, breast cancer
remains the second leading cause of cancer death in women [1]. The greatest reduction
in breast cancer mortality would result from improved clinical management of patients
diagnosed with high-risk tumors, such as those receiving chemotherapy as part of firstline treatment. While chemotherapy exerts direct cytotoxic effects on proliferating cancer
cells, significant effects of chemotherapy are also mediated through immune-boosting
anti-cancer mechanisms [2]. Conversely, emerging evidence from other solid tumor types
indicates that strong intratumoral immunosuppressive mechanisms provide resistance to
chemotherapy [3,4].
A plethora of research has demonstrated association of histological measures of antitumor immune activity with clinical outcome in multiple cancer types, with the main
focus on tumor-infiltrating lymphocytes, particularly CD8+ cytotoxic T cells [5–13]. A
comprehensive meta-analysis showed that the density of tumor-infiltrating lymphocytes is
associated with favorable survival and predictive of pathologic complete response (pCR)
in patients with HER2+ or triple-negative breast cancer (TNBC) subtypes after neoadjuvant
chemotherapy [14]. In addition to the density of tumor-infiltrating lymphocytes [15], their
differential spatial distribution as well as a spatial heterogeneity have prognostic value
in gastrointestinal cancers [16–18], lung cancer [19–21], and breast cancer [22–28]. While
cytotoxic T lymphocytes are tumor suppressive, tumor-associated macrophages (TAMs)
exert immunosuppressive effects [29]. TAMs promote progression of breast cancer and
other solid malignancies via local immunosuppressive, pro-angiogenic and pro-metastatic
effects [30] that include enhancing cancer cell proliferation, invasion, and metastasis [31–33].
A high density of tumor-associated macrophages (TAMs) was significantly associated with
poor survival in patients with breast cancer [14].
TAMs tend to display the M2-like macrophage phenotype and express CD163 [34].
While the pan-macrophage marker CD68 has been mostly used to identify TAMs in breast
cancer tissues in earlier studies [35], more recent studies have established that a high
density of CD163+ TAMs in breast tumors is associated with poor prognosis [36–39]. These
studies each used visual counting of CD163+ TAMs by pathologists but employed different
methodologies to support an association of poor prognosis with elevated CD163+ TAMs
in breast cancer. Medrek and colleagues relied on visual scoring of CD163+ cells in breast
cancer into 4 ordinal categories ranging from 0 (none/absent) up to 3 (strong/dense) and
found that infiltration of CD163+ macrophages into tumor stroma, but not into tumor
nests, had significant association with overall survival in a cohort of 144 patients [36].
Another study reported that high levels of CD163+ TAMs within the subjectively selected
most TAM-enriched breast cancer regions were significantly associated with aggressive
features, such as vessel invasion and non-luminal molecular subgroups and reduced
survival in a cohort of 282 patients [39]. Jeong and colleagues found that a high number
of CD163+ macrophages within tumor nests was an independent prognostic marker of
reduced OS and DFS in 367 breast cancer patients [37]. Jamiyan and colleagues reported
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that infiltration of CD163+ TAMs, rather than CD68+, in both tumor stroma (TS) and tumor
nests (TN) was associated with poor prognosis in patients with triple-negative breast cancer
(TNBC) [38]. That study, similar to earlier reports [40,41], used methodology that involved
initial identification of CD163+ TAM “hotspot” areas (five areas of TN and five areas of
TS) with most abundant macrophages followed by counting the number of CD163-positive
macrophages.
These initial investigations of CD163+ TAMs in breast cancer have largely depended
on research-focused pathologists to visually enumerate the cells, which is both laborious
and subjective, and impedes implementation of these analyses into clinical practice. There is
a great need for objective, machine-based approaches to effectively capture the information
value that can be provided by the density and spatial proximity of CD163+ TAMs in breast
cancer. Furthermore, none of the previously reported studies was focused on addressing
the relationship between immunosuppressive CD163+ TAMs in patients with high-risk
breast cancer who received chemotherapy.
We performed immunofluorescence-based histo-cytometry of CD163+ TAMs on tissue
microarrays representing a retrospective cohort of 443 cases of invasive breast cancer from
patients who subsequently received adjuvant chemotherapy. We developed objective,
operator-independent image analysis methods to quantify the density of CD163+ TAMs
and explored different spatial metrics of proximity to cancer cells as predictors of clinical
outcome. To objectively determine the relationship between clinical outcome and proximity
of CD163+ M2-like TAMs to breast cancer cells, three-color immunofluorescence (IF) images
of breast cancer tissue microarrays were immunolabeled for cytokeratin (CK) and CD163
and counterstained with DAPI. Cell segmentation of digital images were performed by
TissueStudio software (Definiens) followed by R-based procedures to provide spatial
metrics as detailed in Methods and Figure 1.

Cancer cell

CD163+ TAM
o

CD163- stromal cell

Figure 1. Computation of the nearest neighbor distances (NND) from each cancer cell to the nearest
CD163+ cell.

2. Materials and Methods
2.1. Study Design
This retrospective study analyzed archival specimens of primary invasive breast
cancer from Thomas Jefferson University Hospital, Philadelphia, PA and the Clinical
Breast Care Project (CBCP) tumor archive at the Walter Reed National Military Medical
Center, Bethesda, MD. All specimen and data collections were conducted according to
research protocols approved by local Institutional Review Boards. Archival formalin-fixed
and paraffin-embedded specimens of primary invasive breast cancer tissue specimens
from 1988–2010 were collected, reviewed by central pathologist (JAH), and representative
cancer tissue regions were selected for inclusion in tissue microarrays (TMAs). TMAs
were constructed using the Grandmaster tissue arrayer (3DHistech) with 0.6 mm core
size. The specimens from unselected consecutive breast cancer cases were included into
TMAs. The patients inclusion criteria for TMA were available tumor tissue and available
clinical outcome data. Missing select clinico-pathological variable(s) was not an exclusion
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criterion, nor were there other inclusion or exclusion criteria. The study population was
further limited to patients that (i) did not have distant metastases at the time of surgery; (ii)
were treated with adjuvant chemotherapy; (iii) had CD163 stained IHC images that met
the quality control. A small number of patients (9) had duplicated tissue cores. For these
patients, the core with the higher number of CD163+ TAMs was used to compute CD163+
TAM-related metrics.
2.2. Patient Cohort
Patients received postoperative radiotherapy according to the treating physician’s
discretion. The progression-free survival (PFS) was defined as the time from diagnosis
to the evidence of local, regional or distant recurrence. Only patients without distant
metastatic disease at the time of diagnosis were included in the study cohort. The patients
without progression were censored at the last follow-up time. Hormone receptor positivity
was defined according to the definition in use at the time of diagnosis, which by immunohistochemistry ranged from ≥5% to ≥10% positivity during the study period of 1988–2010.
With respect to hormone treatment, patients with HR-positive (HR+) tumors were classified
as “non-compliant” if hormone treatment was recommended but patients did not receive
this treatment.
2.3. Immunohistochemistry
Immunofluorescene immunohistochemistry (IF-IHC), slide scanning, and quantitative
analysis of digitized images were performed in a manner blinded to outcome. Fluorescence
immunohistochemistry for CD163 was performed on an autostainer (Agilent/Dako Omnis)
using anti-CD163 antibody (Cat# HPA046404, 1:4000; Sigma) followed by HRP-conjugated
secondary antibody (Cat# K4003, Agilent) and visualized using Cy5-tyramide as substrate (Cat# NEL745001KT, Perkin Elmer), multiplexed with anti-pan-cytokeratin antibody
(mouse monoclonal AE1/AE3 blend, Cat# M3515, 1:100, Agilent) with Alexa-Fluor-555labeled secondary antibody (Cat# A21422, Thermo Fisher) to identify cancer cells, followed
by counterstaining with DAPI to visualize cell nuclei as previously described [42–44].
Stained slides were scanned at 20× magnification on the Pannoramic Flash 250 scanner
(3DHistech) and fluorescent images were captured in three channels (Cy5, Cy3/Alexa-555
and DAPI). Cell segmentation of digital images was performed by TissueStudio software
(Definiens) and CD163 immunoreactivity was computed for individual cancer cells and
stromal cells for each tumor core. The operators were blinded to patient IDs and clinical
outcomes. Some tissue cores were excluded from further analysis if the quality of the
staining was deemed substandard or if less than 10 cancer cells were identified.
2.4. Identification of CD163+ TAMs
The image data included spatial localization information (x-y coordinates of cell
centroids) for cancer and cells within the tumor stroma. The CD163-signal in cancer cells
in each tissue core were viewed as background noise and were used to compute the 99%
confidence 95% content non-parametric upper tolerance limit (UTL) for background CD163
signals. The quantile cutoffs for UTLs were selected using Table A.16 in [45] with the
smallest sample size of 10 and using linear interpolation for the sample sizes not included
in this table. Cell within tumor stroma were identified as CD163+ TAMs if their CD163
expression levels were above the background UTL for the corresponding tissue core. The
identification procedure for CD163+ TAMs identification was implemented in Python [46].
2.5. Spatial Metrics of Interaction between CD163+ TAMs and Cancer Cells
The spatial localization of cells was jointly considered for cancer cells, CD163+ TAMs,
and CD163- stromal cells, and viewed as a multitype marked point pattern (MMPP) [47].
The resulting MMPPs were used to compute the spatial interaction metrics based on the
distributions of the nearest neighbor distances (NND) between individual cancer cells and
the nearest CD163+ TAM, and CD163+ TAM density metrics. Similar to visual enumeration
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of CD163+ TAMs in a region of interest by a pathologist, we considered the total count
of CD163+ TAMs within the sampled area of each tumor tissue core (0.28 mm2 ). The
proportion of CD163+ TAMs within the stromal compartment of each tumor tissue core
was also computed. Neither of these traditional metrics needs information on the spatial
localization of cancer cells and immune cells. The spatial NND-based metrics included
summary statistics of the NND distributions for each tissue core: (i) 10th percentile, (ii) 25th
percentile (i.e. 1st quartile), and (iii) the median (50th percentile). Figure 1 illustrates the
computation of the NNDs from cancer cells to their nearest CD163+ TAM (grey arrows).
In addition, we considered the average counts of adjacent CD163+ TAMs to each cancer
cell (within 12 µm distance of direct cell-to-cell or juxtacrine signaling) and communicating
CD163+ TAMs to each cancer cell (within 250 µm cyto/chemokine communication or
paracrine signaling distance). The adjacent distance of 12 µm is approximately equal
to the estimated median diameter of cancer cells. The choice of 250 µm is based on
results of Francis and Palsson (1997) who estimated that 250 µm is the maximum tissue
distance over which a single cell can effectively communicate via paracrine cyto/chemokine
signaling) [48]. All spatial metrics were computed using the R package ‘spatstat’ [49]. The
tumor cores that had zero count of CD163+ TAMs (67 of the analyzed 443) were included
in all analyses with the counts-based CD163 metrics equaled to zero and the NND-based
metrics truncated at 600 µm, which is the diameter of the TMA tissue core.
2.6. Dichotomization of CD163 Metrics and Association with Clinicopathologic Characteristics and
Progression-Free Survival
The correlation between CD163 metrics was evaluated using the Spearman correlation
coefficient. The association between CD163 metrics and categorical clinicopathological
factors was evaluated using the Kruskal–Wallis test. The optimal cutoff for each CD163
metrics with the corresponding 90% confidence interval was determined using the bootstrap
approach. First, 1000 bootstrap samples were drawn with replacement from the study
cohort. In each bootstrap sample, the survival tree model with 10-fold cross-validation
(R package rpart [50]) was used to establish an objective data-driven optimal cutoff for
dichotomizing the CD163 metric. The median of the resulting sample of 1000 cutoffs was
used as the optimal cutoff for each CD163 metrics, and the corresponding non-parametric
90% confidence limits are 5th and 95th percentiles of the distribution of 1000 bootstrapbased cutoffs. The association between dichotomized CD163 metrics and categorical
clinicopathological factors was evaluated using the Fisher’s exact test or its extension for
more than 2 categories. For the continuous age variable, the two-sample Wilcoxon SignedRank test was used. The p-values for testing associations between multiple continuous or
dichotomized CD163 metrics and clinicopathological factors were adjusted for multiple
testing using Holm’s method which controls family-wise error rate [51].
Each CD163 metric computed was evaluated as a dichotomized predictor of PFS in a
univariate Cox model and multivariable Cox model that included standard clinicopathological prognostic factors of PFS: age, race (white vs. non-white), histologic grade, node status,
tumor size (<2 cm, 2–5 cm, >5 cm), radiation therapy, chemotherapy, and hormone therapy
non-compliance (vs. the compliant reference category). The parsimonious model was selected a priori including clinicopathological prognostic factors but not the CD163 markers.
The proportional hazards assumption was evaluated for all covariates in the Cox models
and covariates that violated the proportional hazard assumptions were incorporated in the
models as strata variables.
2.7. Internal Validation of Dichotomized CD163 Metrics
The internal validation of dichotomized CD163+ metrics was performed using the
bootstrap optimism correction procedure [52]. Multiple imputation was used for missing
values for clinicopathologic covariates for some patients (0.6% to 10% for all clinicopathological covariates, but higher level for hormone compliance, Table 1, Supplementary Tables S2–S7). Forty (40) imputed datasets were created using the multivariate imputation
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by chained equations (MICE) algorithm. For each covariate, missing values were imputed
by univariate models for corresponding outcome type using the fully conditional specification [53]. The bootstrap optimism correction algorithm was applied to each imputed
data set. Then results for all imputed data sets were averaged using Rubin’s rule [54]. The
following steps of the bootstrap optimism correction algorithm were performed for each
imputed data set. First, 500 bootstrap samples were drawn with replacement from each
imputed data set with all patients. In each bootstrap sample, the survival tree model with
10-fold cross-validation (R package rpart) was used to establish an objective data-driven
optimal cutpoint for dichotomizing the CD163 metric. The cutpoint from the current
bootstrap sample was used to compute the log hazard ratio for the univariate and multivariate Cox models in the current bootstrap sample (“Bootstrap performance”) and in
the main sample (“Test performance”), and the optimism in hazard ratio estimation was
computed as the difference between log hazard ratio for “Bootstrap performance” and for
“Test performance”. The mean optimism estimate was computed as the average optimism
over 500 bootstrap samples. The cutpoint for dichotomizing individual spatial CD163
metrics was also established in the imputed data set and its “apparent performance” was
computed as the log hazard ratio for dichotomized CD163 metric in the multivariable
Cox models. Finally, the optimism-corrected performance estimates were computed by
subtracting the mean optimism estimates from the apparent performance estimates [52].
The optimal cutpoints based on bootstrap samples were used to compute bootstrap-based
non-parametric 90% confidence intervals for dichotomization cutpoints. The outcome and
association analyses were performed using R [55].
Table 1. Associations between dichotomized count of CD163+ cells and other prognostic factors.
Number of CD163+ Cells per 0.28 mm2
Low

High
p (&)

Total N

N

%

N

%

443

377

85%

66

15%

HRHR+
Missing

93
349
1

62
314
1

67%
90%
100%

31
35
0

33%
10%
0%

<0.001

White
Non-White
Unknown

101
333
9

81
288
8

20
45
1

20%
14%
11%

1.000

86%
89%

Histological Grade 1
Histological Grade 2
Histological Grade 3
Missing

119
177
145
2

109
157
109
2

92%
89%
75%
100%

10
20
36
0

8%
11%
25%
0%

0.018

Tumor Size <2 cm
Tumor Size 2–5 cm
Tumor Size >5 cm

214
171
58

191
136
50

89%
80%
86%

23
35
8

11%
20%
14%

1.000

Node Negative
Node Positive
Missing

211
223
9

179
190
8

85%
85%
89%

32
33
1

15%
15%
11%

1.000

Her2 Negative
Her2 Positive
Missing

375
54
14

321
44
12

86%
81%
86%

54
10
2

14%
19%
14%

1.000

Radiation = Yes
Radiation = No

255
188

219
158

86%
84%

36
30

14%
16%

1.000

Horm Tx Non-Compliant
Horm Tx Compliant
Unknown

98
45
207

89
40
186

91%
89%
90%

9
5
21

9%
11%
10%

0.003

(&) adjusted for multiple testing using Holm’s method.
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3. Results
The study cohort included 443 cases of locoregional HR+ and HR- breast cancer treated
with adjuvant chemotherapy for whom tissue sample included at least 10 cancer cells. The
clinical follow-up ranged from 1 month to 238 months with a median follow-up time of
64 months. There were 77 progressions in the study cohort of 443 patients (17.4%). Table 1
details the patient characteristics and their association with the dichotomized standard
metric of CD163+ TAM count per tissue core.
Examples of breast cancer tissue core IF-IHC images are shown in Figure 2A–C
with the corresponding multitype marked point patterns (MMPPs) of cancer cells (green),
CD163+ TAMs (red), and CD163− stromal cells (gray; Figure 2D–F), and the corresponding
distributions of nearest neighbor distances (NNDs) from cancer cells to the nearest CD163+
TAM with metrics of 10th percentile, 25th percentile (lower quartile Q1) and median NNDs
(Figure 2G–I).
For the tumor core presented in Figure 2B, the NND distribution from cancer cells to
CD163+ TAMs (Figure 2H) is reflective of greater proximity (smaller range and smaller
values of all percentiles, including 10th, 25th and median) than the NND distributions in
Figure 2G,I, which corresponds to the tumor cores in Figure 2A,C. Such more proximal
distribution corresponds to a higher prevalence of CD163+ TAMs found next to cancer cells
in MMPP (Figure 2E). In contrast, the majority of CD163+ TAMs in Figures 2D,F are more
separated of from cancer cells and the corresponding NND distributions in Figures 2G,I
are wider and have larger values of all percentiles, including the 10th and 25th percentile
and the median. As described in the Methods section, we also computed alternative spatial
proximity metrics of the average number of CD163+ TAMs that are (i) directly adjacent to
(within 12 µm distance or (ii) within paracrine cyto/chemokine communicating distance
(within 250 µm distance) [48] of each cancer cell.
We first examined the correlations among all CD163+ TAM-related spatial metrics,
including count and proportion of CD163+ TAMs, cancer-to-CD163+ NND-based metrics,
and metrics of CD163+ TAM proximity to cancer cells (average numbers of adjacent or
communicating CD163+ TAMs) (Supplementary Figure S1 and Supplementary Table S1).
As expected, the traditional count of CD163+ TAMs in the tumor core and the proportion
of CD163+ TAMs among stromal cells were highly correlated (coefficient = 0.74; 95% CI:
0.69; 0.78). The average number of communicating CD163+ TAMs was highly correlated
with CD163+ TAM count (coefficient = 0.989; 95% CI: 0.987; 0.991) and stromal cell CD163+
TAM proportion (coefficient = 0.76; 95% CI: 0.71; 0.8) (Supplementary Table S1). The three
NND metrics were highly pairwise correlated, but not as correlated with the count and
proportion or with the metrics of CD163+ TAM proximity to cancer cells (Supplementary
Figure S1). Meanwhile, the two metrics of CD163+ TAM proximity to cancer cells were
substantially correlated (coefficient = 0.55; 95% CI: 0.49; 0.62) (Supplementary Table S1).
Supplementary Figures S2 and S3 present the associations between all CD163+ TAMrelated metrics and clinicopathologic characteristics. Only p-values significant after multiple testing adjustment are shown on the plots. Notably, HR-negative (HR-) tumors had
significantly higher levels of traditional CD163+ TAM count-based metrics and a higher
average number of communicating CD163+ TAMs as compared patients with HR-positive
(HR+) tumors, but no difference between HR- and HR+ tumors was observed in terms of
the NND-based CD163+ TAM metrics or the average number of adjacent CD163+ . Similarly,
higher levels of CD163+ TAM count-based metrics were associated with higher histologic
grade, but no such trend was observed for the NND-based metrics. However, NND-based
CD163+ TAM metrics were higher in Her2-positive as compared to Her2-negative tumors.

Cancers 2022, 14, 308

8 of 17

B

100 µm

E

CD163+

CD163-

Cancer

CD163+

CD163-

Cancer

H

0.000

0

50
100
Distance (µm)

150

0.030

10th percentile
25th percentile
Median

Density
0.015

Density
0.015

10th percentile
25th percentile
Median

CD163+

CD163-

Cancer

I

0.000

0.030

G

F

0

50
100
Distance (µm)

150

0.030

D

100 µm

10th percentile
25th percentile
Median

Density
0.015

100 µm

C

0.000

A

0

50
100
Distance (µm)

150

Figure 2. Spatial analysis of CD163+ TAMs and cancer cells in breast cancer. IF-IHC images ((A–C);
cancer cells green, CD163+ TAMs red) with corresponding marked point patterns (D–F) of CD163+
TAMs (red), CD163− cells (grey), and cancer cells (green), and nearest neighbor distance (NND)
distributions (G–I) for cancer cells to the nearest CD163+ TAM.

We next explored dichotomization for all CD163+ TAM-related metrics. Optimal dichotomization thresholds were identified for each CD163+ TAM-related metric, and all
dichotomized count-based and distance-based metrics remained significant predictors of
progression-free survival (PFS) after bootstrap-based bias correction and adjustment for multiple testing (Table 2). Table 1 and Supplementary Tables S2–S8 present the associations of all
dichotomized CD163+ TAM metrics with the standard clinicopathological prognostic factors
of PFS and adjuvant treatment indicators. Similar to results for continuous CD163+ TAM
metrics, HR- breast tumors have higher proportions of cases with a high total count of CD163+
TAMs and a high number of adjacent or communicating CD163+ TAMs as compared HR+
tumors (Table 1 and Supplementary Tables S6 and S7). Also, high levels of all count-based
CD163+ TAM metrics were associated with higher histological grade (Table 1 and Supplementary Tables S2, S6 and S7), and high CD163+ TAM NND-based metric were associated with
higher proportion of Her2-positive tumors (Supplementary Tables S3–S5). No association
with age was observed for any of the CD163+ TAM metrics (Supplementary Table S8).
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Table 2. Bias-adjusted hazard ratios and optimal cutpoints for dichotomized metrics.
Metric
High vs.
High vs.
High vs.
High vs.
High vs.
High vs.
High vs.

low number of CD163+ TAMs
low proportion of CD163+ TAMs
low 10th PCTL of cancer-to-CD163+ NNDs
low 25th PCTL of cancer-to-CD163+ NNDs
low median cancer-to-CD163+ NND
low average number of adjacent CD163+ TAMs
low average number of communicating CD163+ TAMs

Dichotomization
Threshold (#)

Hazard
Ratio (*)

LL 95%CI

UL 95%CI

p (&)

70 (12–102)
0.038 (0.004–0.149)
13 (7–55)
17 (9–42)
19 (13–74)
0.034 (0.022–0.087)
46 (21–57)

2.97
1.94
0.60
0.46
0.48
2.71
2.96

1.73
1.20
0.38
0.26
0.27
1.70
1.80

5.11
3.14
0.94
0.82
0.85
4.32
4.87

<0.001
0.026
0.027
0.026
0.026
<0.001
<0.001

(#) bootstrap-based 90% confidence interval in parentheses. (&) adjusted for multiple testing using Holm’s method.
(*) bootstrap-based optimistic bias-adjusted hazard ratio.

The highest bias-adjusted effect sizes (hazard ratios) on PFS were observed for the
count of CD163+ TAMs per core (HR = 3.0; 95% CI: 1.7–5.1; p < 0.001) and the number
of communicating CD163+ TAMs (HR = 3.0; 95% CI: 1.8—4.9; p < 0.001), followed by the
number of CD163+ TAMs adjacent to cancer cells (HR = 2.7; 95% CI: 1.7–4.3; p < 0.001).
These CD163+ TAM metrics as well as the median of the cancer cell-to-CD163+ TAM NND
distribution remained significant predictors of PFS in multivariable Cox models adjusted
for significant clinicopathological prognostic factors (Table 3). Each CD163+ TAM metric
was evaluated in separate multivariable Cox model due to high correlations between these
metrics (Supplementary Table S1). The bias-adjusted effect sizes for all CD163+ TAM
metrics in multivariable Cox models are presented in Supplementary Table S9.
In multivariable Cox models adjusted for significant clinicopathological prognostic
factors of PFS, the number of communicating CD163+ TAMs had the largest effect size
(HR = 2.3; 95% CI: 1.4–4.0; p = 0.003), followed by the median of the CD163+ TAM NND
distribution (HR = 1.9; 95% CI: 1.03–3.4; p = 0.024), the count of CD163+ TAMs per core
(HR = 1.9; 95% CI: 1.05–3.4; p = 0.039), and the number of adjacent CD163+ TAMs (HR = 1.8;
95% CI: 1.1–2.9; p = 0.024). For illustration, Figure 3 shows the Kaplan–Meier survival
estimates for these CD163+ TAM metrics dichotomized using the thresholds obtained as
the median threshold in 1000 bootstrap samples (Table 2).
The count-based CD163+ TAM metrics significant in multivariable Cox models were
highly correlated (correlation coefficients ranging from 0.53 to 0.99, Supplementary Table
S1), but the median cancer-to-CD163+ NND was less correlated with all these count-based
CD163+ TAM metrics (correlation coefficients ranging from −0.12 to −0.33; Supplementary
Table S1). Thus, for the secondary analysis, we considered combining the strongest countbased predictor (the number of communicating CD163+ TAMs) with the median cancer-toCD163+ NND. The model with the main effects and interaction between these two metrics
did not yield a significance of interaction term most likely due to the sample size limitation.
However, Kaplan–Meier survival estimates of four combinations of low/high number of
communicating CD163+ TAMs and low/high median cancer-to-CD163+ NND (Figure 4A)
suggested possibly more than 2 different risk categories based on the dichotomized number
of communicating CD163+ TAMs and the median cancer-to-CD163+ NND. Therefore, a
combined CD163+ TAM marker was defined with three risk categories: (1) low number of
communicating CD163+ TAMs and high median cancer-to-CD163+ NND; (2) low number
of communicating CD163+ TAMs and low median cancer-to-CD163+ NND; (3) high number
of communicating CD163+ TAMs and any median cancer-to-CD163+ NND. Figure 4B
shows for illustration the corresponding unadjusted Kaplan–Meier survival estimates
for the resulting three groups. Table 4 shows the results from the multivariable Cox
model including the combined CD163+ TAM marker and significant clinicopathological
prognostic factors with bootstrap-based optimism correction. This model suggests that with
adjustment for known significant clinicopathological prognostic factors, similar extra risk
of progression is associated with a high number of communicating CD163+ TAMs (HR = 2.5;
95% CI: 1.4–4.9; p = 0.002) and with low median cancer-to-CD163+ NND (HR = 2.3; 95% CI:
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1.1–4.6; p = 0.024) as compared to the lowest risk group with a low number of communicating
CD163+ cells and high median cancer-to-CD163+ NND (Table 4). The unadjusted Kaplan–
Meier survival estimates for the resulting three groups suggest higher risk associated with
a high number of communicating CD163+ TAMs than with how median cancer-to-CD163+
NND because of association between hormone receptor status and combined CD163+ TAM
marker. Namely, 33/63 (52%) of tumors with a high number of communicating CD163+
TAMs are HR-, but only 12/81 (15%) of tumors with a low number of communicating CD163+
TAMs and low median cancer-to-CD163+ NND are HR-. Thus, adjustment for hormone
receptor status reduces the effect size for a high number of communicating CD163+ TAMs
in the multivariable Cox model. Meanwhile, the effect of low median cancer-to-CD163+
NND is attributed primarily to HR+ tumors overrepresented in the risk group with low
median cancer-to-CD163+ NND and a low number of communicating CD163+ TAMs.
Table 3. Bias-adjusted results from the parsimonious Cox models with significant CD163 metrics.
Model with Number of CD163+ TAMs

Hazard Ratio (*)

LL 95% CI

UL 95% CI

p-Value

2.01
2.42
1.52
2.74
1.84
1.96
2.93
1.89

0.92
1.05
0.78
1.43
1.10
1.15
1.53
1.05

4.39
5.58
3.00
5.24
3.07
3.36
5.61
3.41

0.086
0.042
0.226
0.004
0.022
0.016
0.002
0.039

Hazard Ratio (*)

LL 95% CI

UL 95% CI

p-Value

2.35
2.87
1.90
2.71
1.78
1.85
2.76
1.88

1.08
1.26
1.00
1.39
1.06
1.08
1.44
1.03

5.11
6.53
3.61
5.28
2.97
3.17
5.30
3.44

0.036
0.015
0.055
0.005
0.032
0.029
0.003
0.024

Hazard Ratio (*)

LL 95% CI

UL 95% CI

p-Value

1.99
2.18
1.71
2.61
1.84
1.97
2.76
1.78

0.91
0.94
0.89
1.37
1.11
1.15
1.44
1.09

4.36
5.04
3.29
4.97
3.07
3.36
5.28
2.89

0.090
0.074
0.111
0.005
0.022
0.016
0.003
0.024

Hazard Ratio (*)

LL 95% CI

UL 95% CI

p-Value

2.25
2.85
1.48
2.55
1.79
1.81
2.77
2.33

1.03
1.24
0.75
1.32
1.08
1.06
1.45
1.37

4.92
6.57
2.91
4.92
2.97
3.09
5.28
3.98

0.045
0.016
0.267
0.008
0.027
0.034
0.003
0.003

Histological Grade 2 vs. 1
Histological Grade 3 vs. 1
HR- vs. HR+ Hormone Tx compliant
HR+ Hormone Tx Non-Compliant vs. Compliant
Node Positive vs. Negative
Tumor Size 2–5 cm vs. <2 cm
Tumor Size >5 cm vs. <2 cm
High vs. Low Number of CD163+ TAMs
Model with Median Cancer-to-CD163+ NND
Histological Grade 2 vs. 1
Histological Grade 3 vs. 1
HR- vs. HR+ Hormone Tx Compliant
HR+ Hormone Tx Non-Compliant vs. Compliant
Node Positive vs. Negative
Tumor Size 2–5 cm vs. <2 cm
Tumor Size >5 cm vs. <2 cm
Low vs. High Median Cancer-to-CD163+ NND
Model with Average Number of Adjacent CD163+ TAMs
Histological Grade 2 vs. 1
Histological Grade 3 vs. 1
HR- vs. HR+ Hormone Tx Compliant
HR+ Hormone Tx Non-Compliant vs. Compliant
Node Positive vs. Negative
Tumor Size 2–5 cm vs. <2 cm
Tumor Size >5 cm vs. <2 cm
High vs. Low Average Number of adjacent CD163+ TAMs
Model with Average Number of Communicating CD163+ TAMs
Histological Grade 2 vs. 1
Histological Grade 3 vs. 1
HR- vs. HR+ Hormone Tx Compliant
HR+ Hormone Tx Non-Compliant vs. Compliant
Node Positive vs. Negative
Tumor Size 2–5 cm vs. <2 cm
Tumor Size >5 cm vs. <2 cm
High vs. Low Average Number of communicating CD163+ TAMs
(*) Bootstrap-based optimistic bias-adjusted hazard ratio.
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Figure 3. Kaplan–Meier plots of PFS by CD163-related markers with the highest prognostic value in
the multivariable Cox model adjusted for significant clinicopathologic risk factors. (A) total number
of CD163+ TAMs in the sampled tumor area (CD163+ Count); (B) median nearest neighbor distance
(median NND) from cancer cells to CD163+ TAMs; (C) the average number of CD163+ TAMs within
12 µm distance of each cancer cell (adjacent CD163+ ); (D) the average number of CD163+ TAMs
within 250 µm distance of each cancer cell (communicating CD163+ ).
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Table 4. Bias-adjusted results from the parsimonious Cox models with combined CD163+
TAM marker.
Predictor

Hazard Ratio (*)

LL 95% CI

UL 95% CI

p-Value

2.17
2.74
1.52
2.67
1.86
1.75
2.81

0.99
1.19
0.77
1.35
1.12
1.02
1.48

4.76
6.31
3.01
5.28
3.09
3.00
5.33

0.056
0.021
0.233
0.007
0.019
0.046
0.002

2.29

1.14

4.63

0.024

2.47

1.42

4.29

0.002

Histological Grade 2 vs. 1
Histological Grade 3 vs. 1
HR- vs. HR+ Hormone Tx Compliant
HR+ Hormone Tx Non-Compliant vs. Compliant
Node Positive vs. Negative
Tumor Size 2–5 cm vs. <2 cm
Tumor Size >5 cm vs. <2 cm
Low vs. High Median Cancer-to-CD163+ NND
AND Low Average Number of communicating CD163+ TAMs
High vs. Low Average Number of communicating CD163+ TAMs
AND High or Low Median Cancer-to-CD163+ NND
(*) Bootstrap-based optimistic bias-adjusted hazard ratio.

1.0
Progression−Free Survival
0.4
0.6
0.8
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Low communicating & High median NND
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Figure 4. Kaplan–Meier plots of PFS by combined CD163+ TAM marker based on high vs. low average number of communicating CD163+ cells and high vs. low median NND. (A) by four combinations
of low/high average number of communicating CD163+ cells and low/high median cancer-to-CD163+
NND; (B) by combined CD163 marker with 3 categories: (1) low average number of communicating
CD163+ cells and high median cancer-to-CD163+ NND; (2) low average number of communicating
CD163+ cells and low median cancer-to-CD163+ NND; (3) high average number of communicating
CD163+ cells and any median cancer-to-CD163+ NND.

4. Discussion
Mounting evidence indicates that high levels of tumor-associated macrophages
(TAMs) [6,25,36,56], and especially CD163+ TAMs of the M2-like phenotype [34,37–39],
are associated with poor prognosis in breast cancer. However, the published evidence
has largely centered on pathologists’ visual enumeration of CD163+ TAMs with limited
capability to objectively capture prognostic value embedded in the spatial relationship
between of CD163+ TAMs and cancer cells. In this study, we developed a novel method
for objective phenotyping of CD163+ TAMs and present new spatial metrics of proximity
of CD163+ TAMs to cancer cells that are independent predictors of clinical outcome in
high-risk breast cancer patients treated with adjuvant chemotherapy. The new algorithm
identifies CD163+ TAMs in an objective manner, independent of subjective assessment by
trained pathologists or by subjective thresholding by the operator of the image analysis
software. The spatial interactions between cancer cells and CD163+ TAMs are quantified
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objectively using the spatial metrics based on nearest neighbor distance (NND) distribution and the average number of CD163+ cells either directly in contact with cancer cells
(adjacent within 12 µm of cancer cells) or within paracrine signaling distance of cancer cells
(communicating within <250 µm distance from cancer cells).
Since the circles with 250 µm radius are comparable in size with the tissue core with
diameter of 600 µm, the CD163+ TAM count and the average count of communicating
CD163+ TAMs are highly correlated in our study. However, the average number of
communicating CD163+ TAMs has the advantage that this metric can be applied directly to
histological images of any size (whole tissue, biopsy or TMA) without the need to select
a tumor region of interest. Moreover, our results indicate that the average number of
communicating CD163+ TAMs is a potentially more informative metric than the traditional
density of CD163+ TAMs within a sampled area of the tumor. Similarly, all NND-based
metrics and the average number of adjacent CD163+ TAMs can be used in tumor images of
any size and can also be computed for other immune cell populations and can be applied
to other solid tumor types. Although we focused on the analysis of breast cancer data,
higher CD163+ TAM density has been shown to be correlated with worse prognosis in
other cancer subtypes such as cutaneous melanoma [57], colorectal carcinoma [58,59],
and ovarian carcinoma [60]. These studies primarily focused on the density of TAMs
rather than spatial arrangements of TAMs. However, some studies showed that increased
CD163+ TAM prevalence was associated with improved clinical outcomes in colorectal
carcinoma [61,62]. Thus, as pointed out by Krijgsman et al. [63], it is critical to characterize
the spatial distribution of TAMs in order to fully understand the association between TAMs
and clinical outcomes.
Our studies of the spatial distribution of CD163+ TAMs differ from previously described quantitative analyses of TAMs in tumor microenvironment in several aspects. First,
virtually all reported studies used trained pathologists to analyze tumor specimens, while
we developed methodology which allowed for the operator-independent identification of
cancer cells and CD163+ TAMs in the tumor stroma. Second, we developed a novel method
for objective phenotyping of CD163+ TAMs that does not rely on subjective identification of
CD163+ TAMs. Third, we present spatial metrics that have not been used in other studies
of CD163+ TAMs in the tumor microenvironment, although NND-based metrics have been
investigated for CD8+ T cells in solid tumors in multiple reports.
The role of tumor-infiltrating lymphocytes (TILs) has been an active area of breast
cancer research [5–13]. There is a potential for association between metrics based on TILs
and TAMs, but such investigation is beyond the scope of this paper, and will be a subject of
further research. Another limitation of our study is that we do not consider the association
between PD-L1 status and CD163+ TAM metrics. Limitations of this study also include
the retrospective analysis of archived tissue samples and the use of TMAs, which provide
limited sampling of each tumor. For a majority of the patients, only one core was included
into the TMA. Our results were internally validated using rigorous statistical analysis,
but validation in independent patient cohort(s) and whole-tissue sections will be needed.
However, more extensive tumor sampling from whole-tissue sections is expected to provide
more accurate data and potentially strengthen the results based on spatial CD163+ TAM
metrics from limited TMA cores.
5. Conclusions
Our results demonstrate for the first time that close spatial proximity of CD163+ TAMs
to cancer cells and the average number of adjacent or communicating CD163+ TAMs are
independent predictors of unfavorable prognosis in breast cancer. In breast cancer patients
who received chemotherapy, we found that the average number of communicating CD163+
TAMs had the largest effect size (hazard ratio) in the multivariable Cox model for PFS
adjusted for known significant clinicopathological risk factors and corrected for optimistic
bias associated with dichotomization. However, the confidence intervals of this hazard
ratio largely overlap with similarly adjusted hazard ratios for the dichotomized median
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cancer-to-CD163+ NND or the average number of adjacent CD163+ TAMs. Hence, it
remains possible that the spatial metrics of median cancer-to-CD163+ NND or the number
of adjacent CD163+ TAMs may become more important predictors than the number of
communicating CD163+ cells in other solid tumors or in distinct breast cancer cohorts, for
instance in different breast cancer subtypes or under different treatment.
Methods to identify breast cancer patients with an elevated risk profile based on
CD163+ TAM-centered tumor markers have the potential to improve clinical management
of patients by identifying patients with unfavorable prognosis and opening the way for
alternative tumor immune-boosting strategies. The present study builds on past progress
of cell density-based tumor analyses and provides new insights into the prognostic significance of spatial proximity of CD163+ TAMs to cancer cells using objective and quantitative
methodologies. The described automated analysis pipeline is readily applicable to both
core needle biopsies and whole-tissue specimens and is expected to be relevant beyond
breast cancer. The prognostic values of CD163+ TAM density and spatial proximity to
breast cancer cells may also be independent prognostic factors in other solid malignancies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers14020308/s1, Figure S1: Scatter plots between all pairs of CD163-related markers.
Figure S2: Boxplots of count-based CD163+ TAM-related metrics by standard clinicopathologic
characteristics., Figure S3: Boxplots of NND-based CD163+ TAM-related metrics by standard clinicopathologic characteristics. Table S1: Correlation coefficients with the corresponding 95% confidence
intervals. Table S2: Associations between dichotomized stromal proportion of CD163+ cells and other
prognostic factors. Table S3: Associations between dichotomized 10th percentile of the NND distribution and other prognostic factors. Table S4: Associations between dichotomized 25th percentile of
the NND distribution and other prognostic factors. Table S5: Associations between dichotomized
median of the NND distribution and other prognostic factors. Table S6: Associations between the dichotomized number of CD163+ cells within 12 µm from cancer and other prognostic factors. Table S7:
Associations between the dichotomized number of CD163+ cells within 250 µm from cancer and
other prognostic factors. Table S8: Associations between age at diagnosis and dichotomized CD163
markers. Table S9: Bias-adjusted hazard ratios from the multivariate parsimonious Cox models with
imputations and including dichotomized CD163 metrics one at a time.
Author Contributions: Conceptualization, H.R. and I.C.; Methodology, H.R., Y.S. and I.C.; Validation,
H.R., Y.S. and A.R.P.; Formal Analysis, B.A.M., M.Y., A.R.P. and I.C.; Resources, H.R., C.D.S., J.A.H.,
A.J.K. and H.H.; Data Curation, Y.S., A.R.P., J.A.H., A.J.K. and H.H.; Writing—Original Draft Preparation, B.A.M., M.Y., H.R. and I.C.; Writing—Review and Editing, B.A.M., M.Y., H.R., I.C., A.R.P., Y.S.,
J.A.H., A.J.K., C.D.S., H.H., M.T.N., T.T., N.S. and L.L.W.; Visualization, A.R.P. and I.C.; Supervision,
H.R. and I.C.; Project Administration, H.R. and I.C.; Funding Acquisition, H.R., C.D.S., J.A.H., A.J.K.,
H.H., T.T. and I.C. All authors have read and agreed to the published version of the manuscript.
Funding: This study was supported in part by funding from grants from the NCI (R01CA222847
(I.C., H.R.), R01CA164225 (L.L.W.), R01CA223804 (L.L.W.)), DOD (W81XWH1910356 (T.T., I.C.),
W81XWH1910357 (H.R.), W81XWH-21-0003 (T.T., H.R., I.C.)), and American Cancer Society (RSG
(L.L.W.), MCWCC Institutional Research Grant #14-247-29 (Y.S.)) and Susan G. Komen Foundation
(Promise Award KG091116 (H.R., A.J.K., J.A.H., H.H., C.D.S., A.R.P., I.C.).
Institutional Review Board Statement: The analyses reported in this study have been conducted
according to the guidelines of the Declaration of Helsinki and were performed with institutional
review board approval of Medical College of Wisconsin (IRB protocol PRO00028590, 02/13/2017).
Informed Consent Statement: Not applicable, the study did not involve human subjects (archival
materials only).
Data Availability Statement: The data sets used and/or analyzed during the current study are
available from the corresponding authors on request.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.

Cancers 2022, 14, 308

15 of 17

Abbreviations
The following abbreviations are used in this manuscript:
CI
CK
IHC
LL
MICE
MMPP
NND
pCR
PCTL
PFS
TAM
TIME
TMA
TN
TNBC
TS
UL
UTL

Cyonfirdence interval
Cytokeratin
Immunohistorychemistry
Lower limit
Multivariate imputation by chained equations
Multitype marked point patterns
Nearest neighbor distance
Pathologic complete response
Percentile
Progression-free survival
Tumor-associated macrophages
Tumor immune microenvironment
Tissue microarray
Tumor nest
Triple-negative breast cancer
Tumor stroma
Upper limit
Upper tolerance limit
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